Interleukin-39 as a Potential Biomarker of Diabetic Neuropathy: A Case–Control Study with ROC Curve Analysis
DOI:
https://doi.org/10.64354/n44khb87Keywords:
IL-39 , Diabetic Neuropathy, Diabetes mellitusAbstract
Background: Diabetic neuropathy is considered the most common prevalent microvascular complication of type 2 diabetes mellitus, manifested by progressive nerve destruction resulting from metabolic and inflammatory mechanisms. The role of IL-39 as a novel pro-inflammatory mediator in diabetic neuropathy has not been clarified yet. Objective: To assess serum levels of IL-39 and evaluate its clinical diagnostic performance in patients with diabetic neuropathy. Methods: This case-control study recruited patients with diabetic neuropathy and healthy controls. Metabolic, glycemic, lipid, and insulin resistance parameters were assessed. Diagnostic accuracy assessed by serum levels of IL-39 measuring and ROC curve analysis was conducted. Results: High IL-39 levels of significance were recorded in diabetic neuropathy patients compared with healthy controls (P < 0.001). The result of ROC curve analysis shows high diagnostic accuracy, indicating strong discriminatory ability
References
References
AHN, J. H., YU, J. H., KO, S. H., KWON, H. S., KIM, D. J., KIM, J. H., KIM, C. S., SONG, K. H., WON, J. C., LIM, S., CHOI, S. H., HAN, K., CHA, B. Y. & KIM, N. H. 2014. Prevalence and determinants of diabetic nephropathy in Korea: Korea national health and nutrition examination survey. Diabetes Metab J, 38, 109-19.
BEAGLEHOLE, R. & YACH, D. 2003. Globalisation and the prevention and control of non-communicable disease: the neglected chronic diseases of adults. Lancet, 362, 903-8.
CALLAGHAN, B. C., CHENG, H. T., STABLES, C. L., SMITH, A. L. & FELDMAN, E. L. 2012. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol, 11, 521-34.
ELNEAM, A. I., MANSOUR, N. M., ZAKI, N. A. & TAHER, M. A. 2016. Serum Interleukin-18 and Its Gene Haplotypes Profile as Predictors in Patients with Diabetic Nephropathy. Open Access Maced J Med Sci, 4, 324-328.
LU, Z., XU, K., WANG, X., LI, Y. & LI, M. 2020. Interleukin 39: a new member of interleukin 12 family. Cent Eur J Immunol, 45, 214-217.
LUO, Y., LIU, F., LIU, H., CHEN, H., CHENG, W., DONG, S. & XIONG, W. 2017. Elevated serum IL-39 in patients with ST-segment elevation myocardial infarction was related with left ventricular systolic dysfunction. Biomark Med, 11, 419-426.
NAVARRO-GONZÁLEZ, J. F., MORA-FERNÁNDEZ, C., MUROS DE FUENTES, M. & GARCÍA-PÉREZ, J. 2011. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol, 7, 327-40.
TUTTLE, K. R., BAKRIS, G. L., BILOUS, R. W., CHIANG, J. L., DE BOER, I. H., GOLDSTEIN-FUCHS, J., HIRSCH, I. B., KALANTAR-ZADEH, K., NARVA, A. S., NAVANEETHAN, S. D., NEUMILLER, J. J., PATEL, U. D., RATNER, R. E., WHALEY-CONNELL, A. T. & MOLITCH, M. E. 2014. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care, 37, 2864-83.
WADA, J. & MAKINO, H. 2016. Innate immunity in diabetes and diabetic nephropathy. Nat Rev Nephrol, 12, 13-26.
WHITING, D. R., GUARIGUATA, L., WEIL, C. & SHAW, J. 2011. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract, 94, 311-21.
YACH, D., HAWKES, C., GOULD, C. L. & HOFMAN, K. J. 2004. The global burden of chronic diseases: overcoming impediments to prevention and control. Jama, 291, 2616-22.
YANG, M. G., TIAN, S., ZHANG, Q., HAN, J., LIU, C., ZHOU, Y., ZHU, J. & JIN, T. 2020. Elevated serum interleukin-39 levels in patients with neuromyelitis optica spectrum disorders correlated with disease severity. Mult Scler Relat Disord, 46, 102430.
YING, L., GONG, L., MENG, S., WU, X., LI, M. & LI, Y. 2023. Circulating interleukin-39 as a potential biomarker for rheumatoid arthritis diagnosis. Clin Biochem, 119, 110616.
Al-Samarrai, A.H. & Al-Taee, S.K. (2022). Interleukin-39 and its association with metabolic and inflammatory parameters in type 2 diabetes mellitus. Journal of Inflammation Research, 15, 123–131.
Callaghan, B.C., Cheng, H.T., Stables, C.L., Smith, A.L. & Feldman, E.L. (2012). Diabetic neuropathy: clinical manifestations and current treatments. The Lancet Neurology, 11(6), 521–534.
Li, X., Wang, Y., Zhang, H. et al. (2022). Emerging roles of IL-39 in inflammatory and metabolic diseases. Cytokine, 150, 155780.
Singleton, J.R., Smith, A.G. & Feldman, E.L. (2015). Microvascular complications of impaired glucose tolerance. Diabetes, 64(4), 1083–1090.
Tesfaye, S., Boulton, A.J.M., Dyck, P.J. et al. (2010). Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care, 33(10), 2285–2293.
Zhang, Q., Liu, S., Ge, D. et al. (2020). Pro-inflammatory role of interleukin-39 in metabolic disorders. International Immunopharmacology, 83, 106408.
Zhou, Y., Wang, X., Li, Y. et al. (2021). Association between lipid profiles and diabetic peripheral neuropathy in type 2 diabetes. Journal of Diabetes Research, 2021, 1–9.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Chemical Interactions
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
